Eurofins, FR0014000MR3

Eurofins completes USD 400 million deal. Eurofins stock trails its high by 0.37 percent

Published on 10/15/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eurofins closed a USD 400 million deal on October 1, 2026. Eurofins stock is EUR 78.93 on October 15, 2026, below its EUR 79.22 high.

Acquisition and reporting dates

  • Eurofins completed the Element transaction for USD 400 million on October 1, 2026.
  • First-half 2026 adjusted earnings per share growth was 29 percent on July 23, 2026.
  • Eurofins stock trades at EUR 78.93 at 10:35 a.m. CEST at Lang & Schwarz on October 15, 2026.
  • The nine-month 2026 trading update is scheduled for October 21, 2026.
Dokumentarische Schwarzweißaufnahme einer Laborantin am Mikroskop mit Probenröhrchen
Schwarzweiß-Reportagefoto dokumentiert Laborarbeit bei Eurofins Scientific SE, ISIN FR0014000MR3, mit Mikroskop und Probenreihen, Illustration mit AI erstellt.

Eurofins stock (ISIN FR0014000MR3) was trading at EUR 78.93 at Lang & Schwarz on October 15, 2026, at 10:35 a.m. CEST, 0.37 percent below its 52-week high of EUR 79.22. The company completed its North American Element acquisition on October 1, 2026, adding a business expected to generate more than USD 150 million in 2026 revenue, according to Eurofins.

Element deal expands North America

The transaction carried an enterprise value of USD 400 million and brought 27 laboratories and facilities into Eurofins. The acquired operations employ about 750 staff and join the group's BioPharma and Life businesses in North America, where the company said its network had been historically underrepresented.

The deal adds a revenue stream equal to more than 2.60 times the purchase value when comparing the expected USD 150 million of annual 2026 revenue with the USD 400 million enterprise value. Profitability is expected to be similar to the Eurofins group average, making integration and margin delivery the key operating test.

Three dated company developments

On July 23, 2026, Eurofins reported first-half progress with adjusted EBITDA margin expansion of 130 basis points and earnings per share growth of 29 percent, according to Eurofins. On October 1, 2026, it completed the divestment of its Electrical and Electronic Testing business to UL Solutions for an enterprise value of EUR 575 million. Also on October 1, 2026, it completed the USD 400 million Element transaction, the latest dated company event.

What dates matter next?

Eurofins plans to publish its nine-month 2026 trading update before the market opens on October 21, 2026, with a conference call at 3:00 p.m. CET. The company will then hold an investor event in Amersfoort, Netherlands, on October 23, 2026, according to Eurofins.

Stock remains near yearly high

The current price is 0.37 percent below the EUR 79.22 52-week high and 43.89 percent above the EUR 54.86 low, using the same October 15, 2026 market snapshot. The company reported EUR 7.296 billion of revenue for fiscal year 2025 and targets a 24 percent adjusted EBITDA margin for fiscal year 2027.

Eurofins was trading at EUR 78.93 at Lang & Schwarz on October 15, 2026, at 10:35 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.

Eurofins stock key facts

  • Company: Eurofins Scientific SE
  • ISIN: FR0014000MR3
  • Ticker: ERF.PA
  • Primary exchange: Euronext Paris
  • Price Lang & Schwarz (as of October 15, 2026, 10:35 a.m. CEST): EUR 78.93
  • 52-week range: EUR 54.86-EUR 79.22 (as of October 15, 2026)
  • Market capitalization: EUR 13.7 billion (as of October 15, 2026)
  • Sector / Industry: Healthcare / Medical Diagnostics and Research

Market context: Market report CAC 40.

More news and analyses on Eurofins stock

Disclaimer...

en | FR0014000MR3 | EUROFINS | boerse | 70327409 | bgmi